南京大学
Nanjing University
名字里带这所大学的医院合在一起算,再加上只署大学名称的论文和试验。
只反映研究活动,不代表医疗水平,也不是医疗建议。 使用说明
鼻咽癌
Nasopharyngeal carcinoma2021–2025年中国大陆共有 2,375 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(23.4%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 1
- 占中国试验的比例
- 0.2%
- 占全球论文的比例
- 0.06%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文2
ClinicalTrials.gov 上的试验1
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025年中国大陆共有 2,923 篇该病的 PubMed 英文论文,这里牵头了其中 26 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(6.9%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 26
- 牵头的试验
- 1
- 占中国试验的比例
- 0.2%
- 占全球论文的比例
- 0.6%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Comparison of clinical and prognostic characteristics between superficial basaloid and conventional esophageal squamous carcinoma.
- Predicting Postoperative Recurrence Using a Support Vector Machine for Patients With Esophageal Squamous Cell Carcinoma: Machine Learning Modeling Development and Validation Study.
- Retrospective Analysis of Risk Factors and Prediction Model of Cervical Anastomotic and Intrathoracic Anastomotic Leakage After Radical Esophagectomy.
- Incidence of MSI-H esophageal carcinoma and related identification of genomic alterations: A multi-center real-world study.
- Effects of immunoenteric nutrition versus general enteral nutrition on prognosis in patients with squamous cell carcinoma undergoing radical esophagectomy post neoadjuvant chemotherapy.
ClinicalTrials.gov 上的试验4
- Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
- A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
- A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
肝细胞癌
Hepatocellular carcinoma2021–2025年中国大陆共有 14,765 篇该病的 PubMed 英文论文,这里牵头了其中 137 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(5.5%)相比。
- 牵头的开放试验
- 3
- 牵头的研究论文
- 137
- 牵头的试验
- 10
- 占中国试验的比例
- 0.7%
- 占全球论文的比例
- 0.5%
这些论文过半是实验室或动物研究。
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial.
- Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
- Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
- Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study.
- Differential HCC risk among HBV indeterminate types at baseline and by phase transition.
ClinicalTrials.gov 上的试验6
- FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma
- Peg IFNα-2b Therapy for Unresectable Mid to Late Stage HBV-HCC
- Clinical Outcomes of HBeAg-negative CHB Patients With Indeterminate Phase
- Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- The Effect of Late-evening Snacks on Patients With Primary Hepatocellular Carcinoma After Hepatectomy
- Applying Artificial Intelligence to Optimize Early-stage Hepatocellular Carcinoma Treatment Based on Multi-modal Image
胃癌
Stomach cancer2021–2025年中国大陆共有 9,782 篇该病的 PubMed 英文论文,这里牵头了其中 145 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(3.9%)相比。
- 牵头的开放试验
- 4
- 牵头的研究论文
- 145
- 牵头的试验
- 18
- 占中国试验的比例
- 1.2%
- 占全球论文的比例
- 0.7%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Efficacy and safety of subserosal versus submucosal carbon nanoparticle-guided laparoscopic radical gastrectomy (DANCE-04): A randomized clinical trial.
- Novel tetrameric bispecific KK-LC-1×CD16A-armed memory-like NK cells enhance antitumor efficacy in gastric cancer.
- NNMT enriches for AQP5+ cancer stem cells to drive malignant progression in early gastric cardia adenocarcinoma.
- Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activation.
- Esophagojejunostomy using a circular stapler after laparoscopic total gastrectomy with pouch suture and multifunctional sealing cap: a simple, safe, and effective anastomosis technique.
ClinicalTrials.gov 上的试验6
- A Study on the Efficacy of Sodium Propionate Combined With Anti-PD-1 Immunotherapy in Gastric Cancer
- Clinical Trial on the Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric Cancer
- Low-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ Cancer
- Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
- Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
视网膜母细胞瘤
Retinoblastoma2021–2025年中国大陆共有 301 篇该病的 PubMed 英文论文,这里牵头了其中 0 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(12.0%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 0
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.0%
骨肉瘤
Osteosarcoma2021–2025年中国大陆共有 2,257 篇该病的 PubMed 英文论文,这里牵头了其中 23 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(4.3%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 23
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.4%
这些论文过半是实验室或动物研究。
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Survival outcomes of patients with brain metastasis of osteosarcoma can be improved by aggressive multi-disciplinary interventions including chemotherapy.
- A case report of rib osteosarcoma and literature review.
- Efficacy and Safety of Treating Refractory Bone and Soft Tissue Sarcoma with Anlotinib in Different Treatment Patterns.
- MiR-18b-3p promotes cell proliferation and metastasis by directly inhibiting PTEN expression in osteosarcoma.
- Intelligent drug codelivery platform for immune microenvironment reconstruction and immunochemotherapy in osteosarcoma treatment.
胃肠道间质瘤
Gastrointestinal stromal tumour2021–2025年中国大陆共有 523 篇该病的 PubMed 英文论文,这里牵头了其中 13 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(6.3%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 13
- 牵头的试验
- 2
- 占中国试验的比例
- 2.7%
- 占全球论文的比例
- 0.8%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Clinical characteristics and prognostic analysis of postoperative recurrence or metastasis of low-risk gastrointestinal stromal tumors.
- Controlling Nutritional Status (CONUT) score as a prognostic marker for gastrointestinal stromal tumours.
- Prognostic analysis of 2-5 cm diameter gastric stromal tumors with exogenous or endogenous growth.
- Risk factors of perforation in gastric stromal tumors during endoscopic resection: a retrospective case-control study.
- Comparison of Modified Cap-Assisted Endoscopic Mucosal Resection and Endoscopic Submucosal Dissection in Treating Intraluminal Gastric Gastrointestinal Stromal Tumor (≤20 mm).
神经母细胞瘤
Neuroblastoma2021–2025年中国大陆共有 1,132 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(8.8%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.05%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
多发性骨髓瘤
Multiple myeloma2021–2025年中国大陆共有 1,676 篇该病的 PubMed 英文论文,这里牵头了其中 21 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(4.8%)相比。
- 牵头的开放试验
- 1
- 牵头的研究论文
- 21
- 牵头的试验
- 4
- 占中国试验的比例
- 0.8%
- 占全球论文的比例
- 0.2%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Licochalcone A suppresses Sp1 expression with potential anti-myeloma activity.
- Clinicopathological characteristics of light chain proximal tubulopathy: a multicentre case series.
- Leveraging diverse cellular stress patterns for predicting clinical outcomes and therapeutic responses in patients with multiple myeloma.
- Construction and validation of an 18F-FDG-PET/CT-based prognostic model to predict progression-free survival in newly diagnosed multiple myeloma patients.
- DKK1 suppresses WWP2 to enhance bortezomib resistance in multiple myeloma via regulating GLI2 ubiquitination.
ClinicalTrials.gov 上的试验6
- Autologous Stem Cell Transplantation for Patients With AL Amyloidosis
- Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
- Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
噬血细胞性淋巴组织细胞增生症
Haemophagocytic lymphohistiocytosis (HLH)2021–2025年中国大陆共有 399 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(22.3%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.1%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
血友病 A
Haemophilia A2021–2025年中国大陆共有 272 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(15.8%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.07%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文2
ClinicalTrials.gov 上的试验5
- To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
- Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
- A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A
- Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.
- ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)
视神经脊髓炎谱系疾病
Neuromyelitis optica spectrum disorder (NMOSD)2021–2025年中国大陆共有 485 篇该病的 PubMed 英文论文,这里牵头了其中 1 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(10.5%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 1
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.05%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
IgG4相关性疾病
IgG4-related disease2021–2025年中国大陆共有 246 篇该病的 PubMed 英文论文,这里牵头了其中 1 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(19.1%)相比。
- 牵头的开放试验
- 1
- 牵头的研究论文
- 1
- 牵头的试验
- 1
- 占中国试验的比例
- 2.3%
- 占全球论文的比例
- 0.08%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
ClinicalTrials.gov 上的试验1
重症肌无力
Myasthenia gravis2021–2025年中国大陆共有 499 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(6.6%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.09%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
烟雾病
Moyamoya disease2021–2025年中国大陆共有 356 篇该病的 PubMed 英文论文,这里牵头了其中 7 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(19.9%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 7
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.6%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- The intraoperative hemodynamic and clinical research of three direct bypasses in moyamoya disease a prospective cohort of 98 cases.
- Long-term clinical and radiological outcomes of extracranial-intracranial bypass in hemorrhagic patients with Moyamoya disease: A single-center observational study of 45 cases.
- Enhanced blood vessel visualization and accelerated image acquisition using spiral magnetic resonance angiography in moyamoya disease: a comparative study with Cartesian magnetic resonance angiograhy.
- Risk Factors for Cerebrovascular Events in Moyamoya Angiopathy Using 4D Flow MRI: A Pilot Study.
- GM-CSF Promotes the Development of Dysfunctional Vascular Networks in Moyamoya Disease.
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025年中国大陆共有 989 篇该病的 PubMed 英文论文,这里牵头了其中 43 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(4.3%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 43
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 1.1%
这些论文过半是实验室或动物研究。
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Air pollution exposure modes, smoking and genetic risk with chronic respiratory diseases: a prospective study.
- Serum cholesterol levels predict the survival in patients with idiopathic pulmonary fibrosis: A long-term follow up study.
- The potential lipid biomarker 5-HETE for acute exacerbation identified by metabolomics in patients with idiopathic pulmonary fibrosis.
- Associations of combined phenotypic ageing and genetic risk with incidence of chronic respiratory diseases in the UK Biobank: a prospective cohort study.
- Diagnostic finding on high-resolution computed tomography (HRCT) predicts a good response to pirfenidone in patients with idiopathic pulmonary fibrosis.
ClinicalTrials.gov 上的试验6
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
- Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
- A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
肌萎缩侧索硬化症
Amyotrophic lateral sclerosis2021–2025年中国大陆共有 779 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(8.3%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.03%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
Alport 综合征
Alport syndrome2021–2025年中国大陆共有 58 篇该病的 PubMed 英文论文,这里牵头了其中 5 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(17.2%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 5
- 牵头的试验
- 1
- 占中国试验的比例
- 16.7%
- 占全球论文的比例
- 1.4%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Dissecting the genotype-phenotype correlation of COL4A5 gene mutation and its response to renin-angiotensin-aldosterone system blockers in Chinese male patients with Alport syndrome.
- Generation of the induced pluripotent stem cell line (NCKDi004-A) from a 17-year-old patient with Alport syndrome carrying a homozygous mutation in COL4A3 gene.
- Genetic features and kidney morphological changes in women with X-linked Alport syndrome.
- Effectiveness of renin-angiotensin-aldosterone system blockers in patients with Alport syndrome: a systematic review and meta-analysis.
- Establishment of the induced pluripotent stem cell line (NCKDi005-A) from a male patient with Alport syndrome carrying a homozygous frameshift mutation in the COL4A4 gene.
ClinicalTrials.gov 上的试验1
IgA 肾病
IgA nephropathy2021–2025年中国大陆共有 736 篇该病的 PubMed 英文论文,这里牵头了其中 13 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(9.4%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 13
- 牵头的试验
- 2
- 占中国试验的比例
- 1.7%
- 占全球论文的比例
- 0.8%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- The prognostic value of hyperhomocysteinemia in IgA nephropathy.
- Early reduction in total cholesterol to high-density lipoprotein cholesterol ratio predicts hydroxychloroquine efficacy in treating IgA nephropathy.
- Hydroxychloroquine blood concentrations and effects in Chinese patients with IgA nephropathy.
- Advancing the application of the analytical renal pathology system in allograft IgA nephropathy patients.
- Primary Cutaneous Mucormycosis Caused by Rhizopus oryzae in a Pediatric Patient with IgA Nephropathy.
ClinicalTrials.gov 上的试验3
- The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy
- Mycophenolate Mofetil Versus Intravenous Cyclophosphamide Pulses in the Treatment of Crescentic IgA Nephropathy
- Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
原发性胆汁性胆管炎
Primary biliary cholangitis2021–2025年中国大陆共有 300 篇该病的 PubMed 英文论文,这里牵头了其中 3 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(12.0%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 3
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.3%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文3
- Prevalence and clinical significance of autoantibodies to sulphite oxidase and glycogen phosphorylase in Chinese primary biliary cholangitis patients.
- Clinical significance of anti-mitochondrial antibodies and PBC-specific anti-nuclear antibodies in evaluating atypical primary biliary cholangitis with normal alkaline phosphatase levels.
- Identifying the genetic association between systemic lupus erythematosus and the risk of autoimmune liver diseases.